Eli Lilly to Press On with Trial Despite Poor Interim Results

Despite interim results showing that Eli Lilly & Co.’s pairing of abemaciclib with Faslodex to fight breast cancer has not produced successful results, the company has been urged to press on with the trial.

A mid-trial review of the company’s Phase 3 testing of the two drugs by an independent data monitoring committee concluded that the trial’s interim efficacy criteria had not been met, the company said. The reason for the recommendation was not disclosed.

The trial involving 669 metastatic breast cancer patients will continue through the first six months of 2017, with the intended endpoint of progression-free survival.